Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Intervention not reported
Nausea/vomiting* grade 3 or 4 (safety population) by type of platinum agent in platinum regimen · women with metastatic breast cancer
The intervention probably leads to lower nausea/vomiting* grade 3 or 4 (safety population) by type of… (moderate certainty).
1 finding from 1 review
Intervention not reported
Anaemia grade 3 or 4 (safety population) by type of platinum agent in platinum regimen · women with metastatic breast cancer
The intervention leads to higher anaemia grade 3 or 4 (safety population) by type of platinum agent… (high certainty).
1 finding from 1 review
Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel may leads to lower response rate ‐ platinum‐sensitive compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer
It is very uncertain whether 175 mg/m2 paclitaxel changes response rate ‐ platinum‐resistant compared with 250 mg/m2 paclitaxel (very low certainty).
1 finding from 1 review
Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐sensitive compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐resistant compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Overall survival, induction platinum + 5-fluorouracil prior to surgery vs surgery alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… showed no clear difference in overall survival, induction platinum + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone (low certainty).
1 finding from 1 review
Overall survival, induction platinum + 5-fluorouracil prior to radiotherapy vs radiotherapy alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… showed no clear difference in overall survival, induction platinum + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone (moderate certainty).
1 finding from 1 review
Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… led to lower disease-free survival, induction platinum + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone; GRADE not reported.
1 finding from 1 review
Locoregional control · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Concomitant (concurrent) chemoradiotherapy led to lower locoregional control, concurrent chemoradiotherapy (platinum +… compared with radiotherapy alone (non-resectable tumours); GRADE not reported.
1 finding from 1 review
RR 0.75 [0.61, 0.93]
3 studies
GRADE not reported
Overall survival ‐ Gemcitabine plus platinum agent · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
1 finding from 1 review
Intervention not reported
Chemobased OS ‐ Platinum‐based chemotherapy OS · patients with resectable gastric cancer
The intervention showed no clear difference in chemobased OS ‐ Platinum‐based chemotherapy OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased DFS ‐ Platinum‐based chemotherapy DFS · patients with resectable gastric cancer
The intervention showed no clear difference in chemobased DFS ‐ Platinum‐based chemotherapy DFS (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found